{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.2","upperLimit":"86.1","value":"72.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"patients achieved the major pathologic response (i.e., \\<10% viable tumor) or pathologic complete response","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nPaclitaxel: Given IV\n\nCarboplatin: Given IV\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab, Paclitaxel, Carboplatin)"}],"paramType":"NUMBER","populationDescription":"number of patients with Major response (Major or complete) was 72.73% (24/33) with a 95% Confidence Interval of 54.2% to 86.1%.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Number of Patients Who Achieved Major Pathologic Response (Defined as 10% or Less Residual Viable Tumor)","type":"SECONDARY","unitOfMeasure":"percentage of major response"}